CL2007000912A1 - Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina. - Google Patents

Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina.

Info

Publication number
CL2007000912A1
CL2007000912A1 CL200700912A CL2007000912A CL2007000912A1 CL 2007000912 A1 CL2007000912 A1 CL 2007000912A1 CL 200700912 A CL200700912 A CL 200700912A CL 2007000912 A CL2007000912 A CL 2007000912A CL 2007000912 A1 CL2007000912 A1 CL 2007000912A1
Authority
CL
Chile
Prior art keywords
rhenine
antihipertensive
administrating
renin
hypertension
Prior art date
Application number
CL200700912A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Satlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38420678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007000912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2007000912A1 publication Critical patent/CL2007000912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200700912A 2006-04-03 2007-04-02 Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina. CL2007000912A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78884206P 2006-04-03 2006-04-03

Publications (1)

Publication Number Publication Date
CL2007000912A1 true CL2007000912A1 (es) 2008-03-14

Family

ID=38420678

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200700912A CL2007000912A1 (es) 2006-04-03 2007-04-02 Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina.

Country Status (20)

Country Link
US (1) US20090062395A1 (enExample)
EP (1) EP2004167A1 (enExample)
JP (1) JP2009532494A (enExample)
KR (1) KR20080108515A (enExample)
CN (1) CN101415413A (enExample)
AU (1) AU2007234917B2 (enExample)
BR (1) BRPI0710095A2 (enExample)
CA (1) CA2645260A1 (enExample)
CL (1) CL2007000912A1 (enExample)
IL (1) IL193905A0 (enExample)
MA (1) MA30387B1 (enExample)
MX (1) MX2008012729A (enExample)
NO (1) NO20084625L (enExample)
NZ (1) NZ571251A (enExample)
RU (1) RU2008143055A (enExample)
SG (1) SG170830A1 (enExample)
TN (1) TNSN08383A1 (enExample)
TW (1) TW200806283A (enExample)
WO (1) WO2007118023A1 (enExample)
ZA (1) ZA200807615B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN102212012A (zh) * 2010-04-12 2011-10-12 上海源力生物技术有限公司 一种合成阿利克伦的中间体及其制备方法
US20140248284A1 (en) 2011-10-20 2014-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the detection and the treatment of cardiac remodeling
CN114072205A (zh) * 2019-04-18 2022-02-18 视点制药公司 用tie-2激活剂治疗高血压的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
WO2006036054A1 (en) * 2004-09-27 2006-04-06 Pantarhei Bioscience B.V. Treatment of prevention of unscheduled bleeding in women on progestogen containing medication

Also Published As

Publication number Publication date
CA2645260A1 (en) 2007-10-18
CN101415413A (zh) 2009-04-22
MX2008012729A (es) 2008-10-14
ZA200807615B (en) 2009-10-28
IL193905A0 (en) 2009-08-03
KR20080108515A (ko) 2008-12-15
JP2009532494A (ja) 2009-09-10
AU2007234917A1 (en) 2007-10-18
WO2007118023A1 (en) 2007-10-18
TW200806283A (en) 2008-02-01
NO20084625L (no) 2008-11-03
TNSN08383A1 (en) 2009-12-29
MA30387B1 (fr) 2009-05-04
US20090062395A1 (en) 2009-03-05
NZ571251A (en) 2011-12-22
SG170830A1 (en) 2011-05-30
BRPI0710095A2 (pt) 2011-08-02
AU2007234917B2 (en) 2011-05-12
EP2004167A1 (en) 2008-12-24
RU2008143055A (ru) 2010-05-10

Similar Documents

Publication Publication Date Title
PA8850801A1 (es) Compuestos útiles para inhibir chk1
ECSP088786A (es) Tratamientos de las alergias oculares
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
GT200900283A (es) &#34;terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario&#34;.
MA32934B1 (fr) Combinaisons inhibitrices hsp90
EA201170872A1 (ru) Ингибиторы протеинкиназы
UY30056A1 (es) Administracion transdermica de meptazinol
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
CL2007003467A1 (es) Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion
SV2016005313A (es) Derivados de carboxamida
CR10199A (es) Derivados de benzimidazol
GT200600160A (es) Tratamiento del dolor
CL2007000912A1 (es) Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina.
CR20140075A (es) Métodos terapéuticos